Biologic Choice Should Be Guided by Disease Severity Not Malignancy in Patients With Inflammatory Bowel Disease

Clin Gastroenterol Hepatol. 2024 Mar;22(3):670-672. doi: 10.1016/j.cgh.2023.07.017. Epub 2023 Aug 4.

Authors

Annie Zhou¹, Ashish Srinivasan², Abhinav Vasudevan²

Affiliations

¹ Department of Gastroenterology, Eastern Health, Victoria, Australia.
² Department of Gastroenterology, Eastern Health, Victoria, Australia; Department of Medicine, Faculty of Medicine Nursing and Health Sciences, Monash University, Victoria, Australia.

PMID: 37543103
DOI: 10.1016/j.cgh.2023.07.017

No abstract available

Publication types

Letter

MeSH terms

Biological Products* / therapeutic use
Humans
Inflammatory Bowel Diseases* / complications
Inflammatory Bowel Diseases* / diagnosis
Inflammatory Bowel Diseases* / pathology
Neoplasms*
Patient Acuity

Substances

Biological Products